KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (ONC) Current Deferred Revenue: 2015-2023

Historic Current Deferred Revenue for BeOne Medicines (ONC) over the last 3 years, with Jun 2023 value amounting to $159.0 million.

  • BeOne Medicines' Current Deferred Revenue fell 2.67% to $159.0 million in Q2 2023 from the same period last year, while for Jun 2023 it was $159.0 million, marking a year-over-year decrease of 2.67%. This contributed to the annual value of $213.9 million for FY2022, which is 28.71% down from last year.
  • BeOne Medicines' Current Deferred Revenue amounted to $159.0 million in Q2 2023, which was down 14.26% from $185.5 million recorded in Q1 2023.
  • In the past 5 years, BeOne Medicines' Current Deferred Revenue registered a high of $300.0 million during Q4 2021, and its lowest value of $17.5 million during Q1 2019.
  • Its 3-year average for Current Deferred Revenue is $153.8 million, with a median of $161.2 million in 2022.
  • Data for BeOne Medicines' Current Deferred Revenue shows a peak YoY increase of 156.89% (in 2022) and a maximum YoY decrease of 28.71% (in 2022) over the last 5 years.
  • Over the past 4 years, BeOne Medicines' Current Deferred Revenue (Quarterly) stood at $17.5 million in 2019, then reached $300.0 million in 2021, then decreased by 28.71% to $213.9 million in 2022, then declined by 2.67% to $159.0 million in 2023.
  • Its last three reported values are $159.0 million in Q2 2023, $185.5 million for Q1 2023, and $213.9 million during Q4 2022.